Investors

Built on a foundation of rigorous science and innovation in drug development.

Stockholder Overview

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company‚Äôs lead product candidate is CPI-818, an investigational, oral, small molecule drug that selectively inhibits ITK and is in a mid-stage clinical trial... 
More  
 

Stock Chart

More  

Upcoming Events

More events are coming soon.

Past Events